{"id":383942,"date":"2020-11-18T08:33:14","date_gmt":"2020-11-18T13:33:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383942"},"modified":"2020-11-18T08:33:14","modified_gmt":"2020-11-18T13:33:14","slug":"kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/","title":{"rendered":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event"},"content":{"rendered":"
\n

\n Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET<\/em>
\n \n <\/p>\n

CELEBRATION, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415 and the anticipated opportunity for the drug product as a potential new entry into the attention deficit hyperactivity disorder (ADHD) marketplace if approved by the U.S. Food and Drug Administration (FDA). The online event will be held on\u00a0Wednesday, December 2, 2020, beginning at 10:00 a.m., ET.<\/p>\n

The event will feature speakers from KemPharm, Corium, and Ann Childress, M.D., President of the Center for Psychiatry and Behavioral Medicine. The speakers will provide an update on the KP415 New Drug Application (NDA) review process, discuss the current ADHD patient and prescriber landscape, and highlight the anticipated KP415 commercialization and launch strategy, if approved. Additional details on how to attend the online event will be provided in a subsequent announcement.<\/p>\n

KP415 is KemPharm\u2019s investigational product candidate for the treatment of ADHD. KP415 consists of serdexmethylphenidate (SDX), KemPharm\u2019s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. KP415 is designed to address unmet needs with the most widely-prescribed methylphenidate ADHD treatments, including earlier onset of action and longer duration of therapy, while avoiding unnecessary spikes in d-MPH concentrations that may be associated with adverse events. The NDA for KP415 is currently under review with the FDA with an anticipated PDUFA date of March 2, 2021.<\/p>\n

Corium, a portfolio company of Gurnet Point Capital (GPC), is leading all commercialization activities for KP415. In September 2019, KemPharm entered into a license agreement with an affiliate of GPC, for the exclusive worldwide rights to develop, manufacture and commercialize certain of KemPharm\u2019s product candidates containing SDX, including KemPharm\u2019s ADHD product candidates, KP415 and KP484.<\/p>\n

\n About KemPharm:<\/strong>\n <\/p>\n

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT\u2122\u00a0(Ligand Activated Therapy) technology.\u00a0KemPharm utilizes its proprietary LAT\u2122\u00a0technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm\u2019s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm\u2019s co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration\/effect profiles. In addition, KemPharm has received FDA approval for APADAZ\u00ae<\/sup>, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com<\/a> or connect with us on Twitter<\/a>, LinkedIn<\/a>, Facebook<\/a> and YouTube<\/a>.<\/p>\n

\n Caution Concerning Forward Looking Statements:<\/strong>\n <\/p>\n

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company\u2019s proposed development and commercial timelines, and can be identified by the use of words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201ccontinue\u201d or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the timing of the PDUFA date and potential FDA approval of the KP415 NDA, the potential commercial launch of KP415, the potential clinical benefits of KP415 or any of the Company\u2019s product candidates, are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm\u2019s business are described in detail in KemPharm\u2019s Annual Report on Form 10-K for the year ended December 31, 2019, KemPharm\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and KemPharm\u2019s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n KemPharm Contacts:<\/strong>
\n
Jason Rando \/ Maureen McEnroe
Tiberend Strategic Advisors, Inc.
<\/a>212-375-2665 \/ 2664
jrando@tiberend.com<\/a>
<\/a>mmcenroe@tiberend.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET CELEBRATION, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415 and the anticipated opportunity for the drug product as a potential new entry into the attention deficit hyperactivity disorder (ADHD) marketplace if approved by the U.S. Food and Drug Administration (FDA). The online event will be held on\u00a0Wednesday, December 2, 2020, beginning at 10:00 a.m., ET. The event will feature speakers from KemPharm, Corium, and Ann Childress, M.D., President of the Center … <\/p>\n

Continue reading “KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383942","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET CELEBRATION, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415 and the anticipated opportunity for the drug product as a potential new entry into the attention deficit hyperactivity disorder (ADHD) marketplace if approved by the U.S. Food and Drug Administration (FDA). The online event will be held on\u00a0Wednesday, December 2, 2020, beginning at 10:00 a.m., ET. The event will feature speakers from KemPharm, Corium, and Ann Childress, M.D., President of the Center … Continue reading "KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T13:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event\",\"datePublished\":\"2020-11-18T13:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/\"},\"wordCount\":760,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/\",\"name\":\"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=\",\"datePublished\":\"2020-11-18T13:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/","og_locale":"en_US","og_type":"article","og_title":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk","og_description":"Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET CELEBRATION, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an online investor event with Corium, Inc. to discuss the potential commercialization strategy for KP415 and the anticipated opportunity for the drug product as a potential new entry into the attention deficit hyperactivity disorder (ADHD) marketplace if approved by the U.S. Food and Drug Administration (FDA). The online event will be held on\u00a0Wednesday, December 2, 2020, beginning at 10:00 a.m., ET. The event will feature speakers from KemPharm, Corium, and Ann Childress, M.D., President of the Center … Continue reading \"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T13:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event","datePublished":"2020-11-18T13:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/"},"wordCount":760,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/","name":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=","datePublished":"2020-11-18T13:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODQyOCMzODMzNTg5IzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kempharm-and-corium-to-co-host-kp415-market-opportunity-and-commercialization-strategy-investor-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KemPharm and Corium to Co-Host \u201cKP415 Market Opportunity and Commercialization Strategy\u201d Investor Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383942"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}